Berman Capital Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Berman Capital Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$3K	Buy	+170	New	+$2.73K	﹤0.01%	1546

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Berman Capital Advisors's ACRS Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Aclaris Therapeutics (ACRS) in Q3 2021: 170 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #1546 among its holdings.

126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

Berman Capital Advisors held 170 shares of Aclaris Therapeutics worth $3K as of Q3 2021.
Aclaris Therapeutics was a new Berman Capital Advisors position in Q3 2021.
Aclaris Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1546 holding.
126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.